SNGX: Soligenix surges on HyBryte results, ‘Has substantial market-share’ says analyst
Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, recently experienced a significant surge in its stock price, driven by the positive outcomes of its HyBryte™ treatment for cutaneous T-cell lymphoma (CTCL). This surge underscores the profound impact of HyBryte’s™ success…